Name | Nilvadipine |
Description | Nilvadipine (FK235), a calcium channel blocker (CCB), is utilized for treatment of hypertension. |
In vitro | In RCS rats' retinas, Nilvadipine significantly increased the expression of rhodopsin kinase and αA-crystallin, while it decreased the expression of caspase-1 and caspase-2. It also entirely inhibited arterial vasoactivity induced by Abeta in rat aortas and human brains. Furthermore, Nilvadipine (0.4 mg/kg i.v. and 2 mg/kg p.o.) was able to reduce paw edema induced by localized ischemia in mice. |
In vivo | In perfused hydronephrotic kidneys, Nilvadipine effectively dilates both afferent and efferent arterioles, enhancing renal blood flow. Moreover, in rat aortic smooth muscle cells (IC50=0.1 nM), Nilvadipine inhibits the chemotactic responses to interleukin-1, leukotriene B4, and platelet-derived growth factor. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 19.3 mg/mL (50 mM) DMSO : 55 mg/mL (142.72 mM), Sonication is recommended.
|
Keywords | FK-235 | inhibit | Ca channels | FR-34235 | Nilvadipine | Calcium Channel | Ca2+ channels | ARC-029 | FK 235 | Inhibitor | ARC 029 | FR 34235 |
Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | Otilonium bromide |
Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |